Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. - Wikidata - wikimedia - TriplyDB

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

http://www.wikidata.org/entity/Q30375000

about

Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model Sm10.3, a member of the micro-exon gene 4 (MEG-4) family, induces erythrocyte agglutination in vitro and partially protects vaccinated mice against Schistosoma mansoni infection An interspecific Nicotiana hybrid as a useful and cost-effective platform for production of animal vaccines The avian influenza vaccine Emerflu. Why did it fail?Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant Influenza immunology evaluation and correlates of protection: a focus on vaccines.Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial Evaluation of multivalent H2 influenza pandemic vaccines in mice.Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge.An overview of the highly pathogenic H5N1 influenza virus.Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen.Impact of antigenic and genetic drift on the serologic surveillance of H5N2 avian influenza viruses.Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant Serologic assays for influenza surveillance, diagnosis and vaccine evaluation.Comparison of serological assays for detecting antibodies in ducks exposed to H5 subtype avian influenza virus Lethal coinfection of influenza virus and Streptococcus pneumoniae lowers antibody response to influenza virus in lung and reduces numbers of germinal center B cells, T follicular helper cells, and plasma cells in mediastinal lymph Node.Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.Immunological assessment of influenza vaccines and immune correlates of protection.An influenza A virus agglutination test using antibody-like polymers.Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans.Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses.Impact of erythrocyte species on assays for influenza serology.

P2860

Q27330580-DE82A6BD-39F9-4B69-B316-09C41C2BC88E Q28541196-AEB4257D-F60B-4FA5-9E78-97909ABDC951 Q28730453-6E20BF29-031F-40F3-AD22-E62E0C544376 Q30203302-73DD3E78-D2BB-4BA3-AB53-FE7BE4FD5988 Q30204573-2F0DDDC2-1287-43E9-A749-7353E437C33E Q30204578-56E73D97-E172-4C54-9D71-368C131BB096 Q30369098-3E62F2B5-88F2-40A2-9016-5D8F5D484111 Q30372087-CF83CF57-2AC6-41AC-A4EB-A47C2A682301 Q30379914-C954B318-17F7-4770-8947-34849EA275BA Q30381280-A03A4F16-4743-499C-8D48-963FD29496A4 Q30385397-39F96CA2-F26C-42DF-AA95-6631E94C0894 Q30388531-6726E24F-CD2A-42A1-A2B1-A88C9E298A56 Q30392895-10EF1D58-07DA-4029-B171-8F341AF0BA39 Q30397652-CAC593B0-F274-4224-9DD0-80230F58BDE1 Q30398507-5435D989-ACD4-4830-B71C-023363F2465A Q30404512-BC270BDA-A1E0-4C9A-B88E-5E4D18677FA0 Q30405955-78EE1718-1DE0-4BEF-B207-4EE291C5F9AF Q30406365-3922D031-7169-457D-A193-177CEBEFF8A2 Q30419240-DF25E108-805A-40B0-82D9-AC3602FF3CCD Q30425590-833843A6-649A-4DD4-9155-BF5B7C1FD2C2 Q30426011-BFE7AB22-7B2E-45EC-9549-2F9A2E673AEE Q33741316-418D0DC9-A7FC-44DF-84F4-486D11C0222E Q33776223-881D3D2C-BC76-4869-AA32-6EA9534911E0 Q33808135-9643B879-BA94-4AC4-9747-F9F3665292DD Q34194336-3645E6BD-35FC-416D-B9C9-8C476E240FE5 Q34348163-C0765901-0B5D-4679-A0DB-CDEC113EA4EF Q35115579-B3789F8E-2698-4CED-9E8E-B4ED81134A1A Q35167137-B88C10D7-9734-4D22-9F35-92BF07DD2F15 Q35826733-5D9DC606-1F6A-45EB-B797-1BCCBEA2EB0D Q36410040-0567920B-D432-481A-A682-324A5E07949F Q36665657-25D34B11-8791-4F68-AC13-F180C7BB65E3 Q38105339-E641B8D8-C330-4D02-8BB9-7DBAE3C90C49 Q40177269-D6032041-A2C0-439A-B698-5F16C96151AE Q40374569-C6E2DB27-3864-4518-9FF1-AAA0E1267F83 Q40551533-BDB90816-A984-41CE-934D-7F6D6DABACA1 Q52673291-7B3F673A-5A71-4EA6-AD9C-A3E18F85A08E Q55239857-1EEAAD06-75A5-4C07-9B1F-02047129C783

P2860

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

http://www.wikidata.org/entity/Q30375000

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Qualification of the hemagglut ...... c influenza vaccine licensure.

@ast

Qualification of the hemagglut ...... c influenza vaccine licensure.

@en

type

label

Qualification of the hemagglut ...... c influenza vaccine licensure.

@ast

Qualification of the hemagglut ...... c influenza vaccine licensure.

@en

prefLabel

Qualification of the hemagglut ...... c influenza vaccine licensure.

@ast

Qualification of the hemagglut ...... c influenza vaccine licensure.

@en

P1433

Q30375000-39571766-8F0E-4F36-9AF0-5DAE91E98647

P1476

Q30375000-82466342-3009-4F1C-BE84-4DD6E7710465

P2093

Q30375000-1CE20EA7-C1FD-4CE7-9D30-7B458B95BE9D

Q30375000-27B6ED77-B132-4517-85FF-2C36FFB70180

Q30375000-42B5B36F-1519-40DE-8834-0FA62B4BCAA4

Q30375000-6E4E5A2E-B64F-406F-B4D2-6955C2F20494

Q30375000-CADBE4B3-3B50-4A41-B25C-C3CDCF98E1B4

P2860

Q30375000-7739E2AA-AC9B-4F02-8466-B51EA413CB50

Q30375000-AE3FA77B-04FF-4FCE-9898-424FE02E352F

Q30375000-DC73574E-46DC-41C0-8835-77A790B0A4B4

P304

Q30375000-4652F89D-7294-4DC5-8BB1-3DDEDE87A8B7

P31

Q30375000-C836340A-4D0D-4720-9BA5-A12EADE3AE2D

P356

Q30375000-3D0D8884-1D0A-4781-8AA6-43914070A4D5

P433

Q30375000-E73A925E-FB0E-4AFC-B1F1-8EF004F87349

P478

Q30375000-085FA23A-3A17-48F6-80BE-75747A56765E

P577

Q30375000-5407D520-60B6-4ECA-AF99-4FAF902BE45B

P5875

Q30375000-8FD3520B-E941-46CF-9358-8D314B830A3D

P698

Q30375000-3A82FAAC-0C15-42E0-AF3A-FF152FD8AB4A

P921

Q30375000-BDB6D879-8891-4325-A23E-38C4E0263BB7

P932

Q30375000-B1AEE5A3-CEBA-4612-BD48-1C2DEE7ABADB

P356

P1433

Clinical and Vaccine Immunology

P1476

Qualification of the hemagglut ...... c influenza vaccine licensure.

@en

P2093

David Hines

http://www.w3.org/2001/XMLSchema#string

Diana L Noah

http://www.w3.org/2001/XMLSchema#string

E Lucile White

http://www.w3.org/2001/XMLSchema#string

Heather Hill

http://www.w3.org/2001/XMLSchema#string

Mark C Wolff

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

P304

558-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00368-08

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24023065

http://www.w3.org/2001/XMLSchema#string

P698

19225073

http://www.w3.org/2001/XMLSchema#string

P921

P932

2668270

http://www.w3.org/2001/XMLSchema#string